Current Neurology and Neuroscience Reports

, Volume 6, Issue 2, pp 156–162

Differential diagnosis in hypersomnia

Article

Abstract

Hypersomnia includes a group of disorders in which the primary complaint is excessive daytime sleepiness. Chronic hypersomnia is characterized by at least 3 months of excessive sleepiness prior to diagnosis and may affect 4% to 6% of the population. The severity of daytime sleepiness needs to be quantified by subjective scales (at least the Epworth sleepiness scale) and objective tests such as the multiple sleep latency test. Chronic hypersomnia does not correspond to an individual clinical entity but includes numerous different etiologies of hypersomnia as recently reported in the revised International Classification of Sleep Disorders. This review details most of those disorders, including narcolepsy with and without cataplexy, idiopathic hypersomnia with and without long sleep time, recurrent hypersomnia, behaviorally induced insufficient sleep syndrome, hypersomnia due to medical condition, hypersomnia due to drug or substance, hypersomnia not due to a substance or known physiologic condition, and also sleep-related disordered breathing and periodic leg movement disorders.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Gelineau JB: De la narcolepsie. Gazette des Hõpitaux (Paris) 1880, 53:626–628.Google Scholar
  2. 2.
    Guilleminault C, Tilkian A, Dement WC: The sleep apnea syndromes. Ann Rev Med 1976, 27:465–484.PubMedCrossRefGoogle Scholar
  3. 3.
    American Academy of Sleep Medicine: International Classification of Sleep Disorders, 2nd Edition: Diagnostic and Coding Manual. Westchester, Illinois: American Academy of Sleep Medicine; 2005.Google Scholar
  4. 4.
    Besset A: Assessing sleepiness. In Sleep: Physiology, Investigations and Medicine. Edited by Billiard M. New York: Kluwer Academic/Plenum Publishers; 2003:169–184.Google Scholar
  5. 5.
    Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540–545.PubMedGoogle Scholar
  6. 6.
    Carskadon MA, Dement WC, Mitler MM, et al.: Guidelines for the Multiple Sleep Latency test (MSLT): a standard measure of sleepiness. Sleep 1986, 9:519–524.PubMedGoogle Scholar
  7. 7.
    Mitler MM, Gujavarty KS, Browman CP: Maintenance of wakefulness test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. Electroencephalogr Clin Neurophysiol 1982, 53:658–661.PubMedCrossRefGoogle Scholar
  8. 8.
    Dauvilliers Y, Billiard M, Montplaisir J: Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003, 114:2000–2017.PubMedCrossRefGoogle Scholar
  9. 9.
    Hublin C, Kaprio J, Partinen M, et al.: The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann Neurol 1994, 35:709–716.PubMedCrossRefGoogle Scholar
  10. 10.
    Dauvilliers Y, Montplaisir J, Molinari N, et al.: Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001, 57:2029–2033. First evidence of a bimodal distribution of age at onset in narcolepsyPubMedGoogle Scholar
  11. 11.
    Dauvilliers Y, Maret S, Bassetti C, et al.: A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. Neurology 2004, 62:2137–2138. First report of monozygotic twins discordant for narcolepsy and CSF hypocretin-1 levels that supports the multifactorial model for the development of narcolepsy with a strong influence of environmental factors.PubMedGoogle Scholar
  12. 12.
    Mignot E, Lin L, Rogers W, et al.: Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2000, 68:686–699. A thorough analysis of HLA DR and DQ association with narcolepsy-cataplexy.CrossRefGoogle Scholar
  13. 13.
    Peyron C, Faraco J, Rogers W, et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991–997. Establishes that hypocretin deficiency is due to the absence of hypocretin-containing neurons in the hypothalamus of human narcolepsy patients.PubMedCrossRefGoogle Scholar
  14. 14.
    Mignot E, Lammers GJ, Ripley B, et al.: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553–1562. Major evidence for hypocretin deficiency in human narcolepsy patients.PubMedCrossRefGoogle Scholar
  15. 15.
    Dauvilliers Y, Baumann CR, Carlander B, et al.: CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and others hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003, 74:1667–1673. Evidence for hypocretin deficiency in symptomatic episodes in KLS.PubMedCrossRefGoogle Scholar
  16. 16.
    Lin L, Faraco J, Li R, et al.: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365–376.PubMedCrossRefGoogle Scholar
  17. 17.
    Taheri S, Zeitzer JM, Mignot E: The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 2002, 25:283–313.PubMedCrossRefGoogle Scholar
  18. 18.
    Nakayama J, Miura M, Honda M, et al.: Linkage of human narcolepsy with HLA association to chromosome 4p13-q21. Genomics 2000, 65:84–86.PubMedCrossRefGoogle Scholar
  19. 19.
    Dauvilliers Y, Blouin JL, Neidhart E, et al.: A narcolepsy susceptibility locus maps to a 5mb region of chromosome 21q. Ann Neurol 2004, 56:382–388. First linkage analysis in human narcolepsy in chromosome 21q.PubMedCrossRefGoogle Scholar
  20. 20.
    U.S. Modafinil in Narcolepsy Multicenter Study Group: Randomized trial of Modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998, 43:88–97.CrossRefGoogle Scholar
  21. 21.
    U.S. Xyrem® Multicenter Study Group: A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002, 25:42–49. First well-designed study that confirms that sodium oxybate signi ficantly improved cataplexy and EDS in patients with narcolepsy.Google Scholar
  22. 22.
    Dauvilliers Y, Carlander B, Rivier F, et al.: Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004, 56:905–908. Open trial in favor of successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset.PubMedCrossRefGoogle Scholar
  23. 23.
    Billiard M, Dauvilliers Y: Idiopathic hypersomnia. Sleep Med Rev 2001, 5:351–360. Extensive review on idiopathic hypersomnia.Google Scholar
  24. 24.
    Roth B, Nevsimalova S, Rechtschaffen A: Hypersomnia with "sleep drunkenness". Arch Gen Psychiatry 1972, 26:456–462.PubMedGoogle Scholar
  25. 25.
    Bassetti C, Aldrich MS: Idiopathic hypersomnia. A series of 42 patients. Brain 1997, 120:1423–1435.PubMedCrossRefGoogle Scholar
  26. 26.
    Broughton R, Nevsimalova S, Roth B: The socioeconomic effects (including work, education, recreation and accidents) of idiopathic hypersomnia. Sleep Res 1978, 7:217.Google Scholar
  27. 27.
    Guilleminault C, Stoohs R, Clerk A, et al.: A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993, 104:781–787.PubMedCrossRefGoogle Scholar
  28. 28.
    Bastuji H, Jouvet M: Successful treatment of IH and narcolepsy with Modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988, 12:695–700.PubMedCrossRefGoogle Scholar
  29. 29.
    Critchley M: Periodic hypersomnia and megaphagia in adolescent males. Brain 1962, 85:627–656.PubMedCrossRefGoogle Scholar
  30. 30.
    Dauvilliers Y, Mayer G, Lecendreux M, et al.: Kleine-Levin syndrome: an autoimmune hypothesis based on clinical and genetic analyses. Neurology 2002, 59:1739–1745. First evidence of an association with KLS and HLA DQB1*0201 that suggests an autoimmune etiology.PubMedGoogle Scholar
  31. 31.
    Billiard M, Guilleminault C, Dement WC: A menstruation-linked periodic hypersomnia. Kleine-Levin syndrome or new clinical entity? Neurology 1975, 25:436–443.PubMedGoogle Scholar
  32. 32.
    Arnulf I, Zeitzer JM, File J, et al.: Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain 2005, In press.Google Scholar
  33. 33.
    Carskadon MA, Dement WC: Cumulative effects of sleep restriction on daytime sleepiness. Psychophysiology 1981, 18:107–113.PubMedCrossRefGoogle Scholar
  34. 34.
    Autret A, Lucas B, Mondon K, et al.: Sleep and brain lesions: a critical review of the literature and additional new cases. Neurophysiol Clin 2001, 31:356–375.PubMedCrossRefGoogle Scholar
  35. 35.
    Guilleminault C, Quera-Salva MA, Goldberg MP: Pseudo-hypersomnia and pre-sleep behaviour with bilateral paramedian thalamic lesions. Brain 1993, 116:1549–1563.PubMedCrossRefGoogle Scholar
  36. 36.
    Gibbs JW, Ciafaloni E, Radtke RA: Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy. Sleep 2002, 25:672–675.Google Scholar
  37. 37.
    Guilleminault C, Yuen KM, Gulevich MG, et al.: Hypersomnia after head-neck trauma: a methodological dilemma. Neurology 2000, 54:653–659.PubMedGoogle Scholar
  38. 38.
    von Economo C: Grippe, encephalitis und encephalitis lethargica. Klin Wochens Wien 1919, 32:393–396.Google Scholar
  39. 39.
    Guilleminault C, Mondini S: Mononucleosis and chronic daytime sleepiness. A long-term follow-up study. Arch Intern Med 1986, 146:1333–1335.PubMedCrossRefGoogle Scholar
  40. 40.
    Buguet A, Bourdon L, Bouteille B, et al.: The duality of sleeping sickness: focusing on sleep. Sleep Med Rev 2001, 5:139–153. Extensive review on the parasitic disease caused by Trypanososma brucei.PubMedCrossRefGoogle Scholar
  41. 41.
    Guilleminault C, Brooks SN: Excessive daytime sleepiness: a challenge for the practising neurologist. Brain 2001, 124:1482–1491.PubMedCrossRefGoogle Scholar
  42. 42.
    Roehrs T, Roth T: Sleep, sleepiness, sleep disorders and alcohol use and abuse. Sleep Med Rev 2001, 5:287–297.PubMedCrossRefGoogle Scholar
  43. 43.
    Billiard M, Dolenc L, Aldaz C, et al.: Hypersomnia associated with mood disorders: a new perspective. J Psychosom Res 1994, 38:41–47.PubMedCrossRefGoogle Scholar
  44. 44.
    Nofzinger EA, Thase ME, Reynolds CF, et al.: Hypersomnia in bipolar depression: a comparison with narcolepsy using the multiple sleep latency test. Am J Psychiatry 1991, 148:1177–1181.PubMedGoogle Scholar
  45. 45.
    Rosenthal NE, Sack DA, Gillin JC, et al.: Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 1984, 41:72–80.PubMedGoogle Scholar
  46. 46.
    Krieger J: Obstructive sleep apnoea-hypopnea syndrome and upper airway resistance syndrome. In Sleep: Physiology, Investigations and Medicine. Edited by Billiard M. New York: Kluwer Academic/Plenum Publishers; 2003:357–389.Google Scholar
  47. 47.
    Sullivan CE, Issa FG, Berthon-Jones M, et al.: Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1981, i:862–865.CrossRefGoogle Scholar
  48. 48.
    Nicolas A, Lesperance P, Montplaisir J: Is excessive daytime sleepiness with periodic leg movements during sleep a specific diagnostic category? Eur Neurol 1998, 40:22–26.PubMedCrossRefGoogle Scholar
  49. 49.
    Hening WA, Allen RP, Earley CJ, et al.: An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004, 27:560–583.PubMedGoogle Scholar
  50. 50.
    Standards of Practice Committee of the American Academy of Sleep Medicine: Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine report. Sleep 2004, 27:557–559.Google Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Neurology DepartmentGui de Chauliac HospitalMontpellierFrance

Personalised recommendations